Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ivan Foeldvari

Showing results (51-60 of 174) with videos related to

Pageof 18
Sort By:
Arthritis & Rheumatology (Hoboken, N.J.)|April 21, 2015
Efficacy and safety of etanercept in patients with the enthesitis-related arthritis category of juvenile idiopathic arthritis: results from a phase III randomized, double-blind studyGerd Horneff, Ivan Foeldvari, Kirsten Minden, et al.
The Lancet. Child & Adolescent Health|April 28, 2023
Off-label is not always off-evidence: authorising paediatric indications for old medicinesSaskia N de Wildt, Ivan Foeldvari, Angeliki Siapkara, et al.
Rheumatology (Oxford, England)|December 3, 2015
Efficacy and safety of biological agents for systemic juvenile idiopathic arthritis: a systematic review and meta-analysis of randomized trialsSimon Tarp, Gil Amarilyo, Ivan Foeldvari, et al.
Seminars in Arthritis and Rheumatism|December 20, 2016
Biological agents in polyarticular juvenile idiopathic arthritis: A meta-analysis of randomized withdrawal trialsGil Amarilyo, Simon Tarp, Ivan Foeldvari, et al.
The Journal of Rheumatology|March 9, 2007
Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational surveyIvan Foeldvari, Susanne Nielsen, Jasmin Kümmerle-Deschner, et al.
Rheumatology (Oxford, England)|June 26, 2012
Juvenile and young adult-onset systemic sclerosis share the same organ involvement in adulthood: data from the EUSTAR databaseIvan Foeldvari, Alan Tyndall, Francesco Zulian, et al.
Rheumatology International|September 13, 2017
An international SUrvey on non-iNvaSive tecHniques to assess the mIcrocirculation in patients with RayNaud's phEnomenon (SUNSHINE survey)Francesca Ingegnoli, Nicola Ughi, Graham Dinsdale, et al.
Arthritis Research & Therapy|November 24, 2017
Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registryGerd Horneff, Anna Carina Schulz, Jens Klotsche, et al.
Rheumatology (Oxford, England)|June 2, 2009
Safety and efficacy of once weekly etanercept 0.8 mg/kg in a multicentre 12 week trial in active polyarticular course juvenile idiopathic arthritisGerd Horneff, Annette Ebert, Sigrid Fitter, et al.
The Journal of Pediatrics|December 17, 2017
Comorbidity of Type 1 Diabetes Mellitus in Patients with Juvenile Idiopathic ArthritisSandra Schenck, Joachim Rosenbauer, Martina Niewerth, et al.
Pageof 18

Showing results (51-60 of 174) with videos related to

Sort By:
Pageof 18
Arthritis & Rheumatology (Hoboken, N.J.)|April 21, 2015
Efficacy and safety of etanercept in patients with the enthesitis-related arthritis category of juvenile idiopathic arthritis: results from a phase III randomized, double-blind studyGerd Horneff, Ivan Foeldvari, Kirsten Minden, et al.
The Lancet. Child & Adolescent Health|April 28, 2023
Off-label is not always off-evidence: authorising paediatric indications for old medicinesSaskia N de Wildt, Ivan Foeldvari, Angeliki Siapkara, et al.
Rheumatology (Oxford, England)|December 3, 2015
Efficacy and safety of biological agents for systemic juvenile idiopathic arthritis: a systematic review and meta-analysis of randomized trialsSimon Tarp, Gil Amarilyo, Ivan Foeldvari, et al.
Seminars in Arthritis and Rheumatism|December 20, 2016
Biological agents in polyarticular juvenile idiopathic arthritis: A meta-analysis of randomized withdrawal trialsGil Amarilyo, Simon Tarp, Ivan Foeldvari, et al.
The Journal of Rheumatology|March 9, 2007
Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational surveyIvan Foeldvari, Susanne Nielsen, Jasmin Kümmerle-Deschner, et al.
Rheumatology (Oxford, England)|June 26, 2012
Juvenile and young adult-onset systemic sclerosis share the same organ involvement in adulthood: data from the EUSTAR databaseIvan Foeldvari, Alan Tyndall, Francesco Zulian, et al.
Rheumatology International|September 13, 2017
An international SUrvey on non-iNvaSive tecHniques to assess the mIcrocirculation in patients with RayNaud's phEnomenon (SUNSHINE survey)Francesca Ingegnoli, Nicola Ughi, Graham Dinsdale, et al.
Arthritis Research & Therapy|November 24, 2017
Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registryGerd Horneff, Anna Carina Schulz, Jens Klotsche, et al.
Rheumatology (Oxford, England)|June 2, 2009
Safety and efficacy of once weekly etanercept 0.8 mg/kg in a multicentre 12 week trial in active polyarticular course juvenile idiopathic arthritisGerd Horneff, Annette Ebert, Sigrid Fitter, et al.
The Journal of Pediatrics|December 17, 2017
Comorbidity of Type 1 Diabetes Mellitus in Patients with Juvenile Idiopathic ArthritisSandra Schenck, Joachim Rosenbauer, Martina Niewerth, et al.
Pageof 18